These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 14991194)

  • 1. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 3. [LEVOSIMENDAN--THE FIRST 10 YEARS IN CLINICAL PRACTICE].
    Rybka MM; Lobacheva GV
    Anesteziol Reanimatol; 2015; 60(5):80-4. PubMed ID: 26852586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of Levosimendan in intensive care treatment of myocardial insufficiency].
    Rehberg S; Ertmer C; Van Aken H; Lange M; Bröking K; Morelli A; Westphal M
    Anaesthesist; 2007 Jan; 56(1):30-43. PubMed ID: 17131137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with advanced heart failure and the effects of levosimendan.
    Song ZZ; Ma J
    Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative use of levosimendan: best practice in operative settings.
    Toller W; Algotsson L; Guarracino F; Hörmann C; Knotzer J; Lehmann A; Rajek A; Salmenperä M; Schirmer U; Tritapepe L; Weis F; Landoni G
    J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):361-6. PubMed ID: 22658687
    [No Abstract]   [Full Text] [Related]  

  • 15. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients.
    Parissis JT; Farmakis D; Bistola V; Adamopoulos S; Kremastinos DT
    Am J Cardiol; 2007 Jan; 99(1):146-7. PubMed ID: 17196480
    [No Abstract]   [Full Text] [Related]  

  • 17. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 18. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 19. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.